Young Investigator Recognized for Leadership on AKI Biomarkers

Chirag R. Parikh, MD, PhD

/kidneynews/9_10_11/42a/graphic/42af1.jpg

The ASN-AHA Young Investigator Award and Address will be presented to Chirag R. Parikh, MD, PhD, who will speak on “Biomarkers for Phenotyping Clinical AKI: Optimizing Questions, Tools, and Trials” on Sunday, Nov. 5.

Dr. Parikh is professor of medicine and investigative medicine and director of the Program of Applied Translational Research at the Yale School of Medicine.

Recognized internationally for his accomplishments in the study of AKI and biomarkers, Dr. Parikh is leading a paradigm change by generating evidence for various clinical applications of structural injury biomarkers in AKI. He has created major multi-disciplinary consortia, developed a large biosample repository, and designed a robust mentoring program to pave the way for continued research innovation.

In 2005, Dr. Parikh established the Translational Research Investigating Biomarker End-points (TRIBE) Consortium, a multidisciplinary collaboration of 11 academic centers in North America. Funded by the National Institutes of Health (NIH), the TRIBE Consortium has conducted several prospective cohort studies for the discovery and validation of kidney biomarkers. It has enrolled more than 5000 patients to evaluate complications after cardiac surgery and collected over 500,000 blood and urine samples to evaluate the role of kidney injury markers of apoptosis, inflammation, injury, and repair. This effort enabled Dr. Parikh to perform the largest validation study to date of urinary biomarkers in kidney injury after cardiac surgery, which has resulted in the development of several biomarkers.

Dr. Parikh was also among the first to provide evidence that AKI is not simply a temporary and reversible co-morbidity, but rather a condition associated with long-term mortality and chronic kidney disease. He published the first study to demonstrate the association of longer-term mortality with kidney injury biomarkers. His findings are being translated rapidly to clinical practice by the inclusion of structural biomarkers in upcoming AKI guidelines.

In addition to his work in AKI, Dr. Parikh has initiated large, NIH-funded, multicenter studies in the areas of deceased-donor kidney transplantation, hepatorenal syndrome, HIV nephropathy, and diabetic kidney disease. Dr. Parikh has published more than 250 peer-reviewed articles.

Dr. Parikh has received consistent outstanding teacher reviews from medical students and nephrology fellows. He has attracted so many fellows and residents to his research program that his trainees are listed as the first author on more than 70 publications. In 2011, he received the prestigious NIH K24 Mid-Career Research Mentoring Award.

Dr. Parikh earned his MD from Seth G.S. Medical College in Mumbai and completed his internal medicine training at Nassau University Hospital and SUNY Stony Brook in New York. He completed his nephrology fellowship and earned his PhD in clinical investigation at the University of Colorado School of Medicine.

October/November 2017 (Vol. 9, Number 10 & 11)